Literature DB >> 17519121

Analysis of antihypertensive effects of statins.

Haralampos J Milionis1, Evagelos N Liberopoulos, Moses S Elisaf, Dimitri P Mikhailidis.   

Abstract

Hypertension and hyperlipidemia, two powerful risk factors of cardiovascular disease (CVD), often coexist. Therefore, treatment should consider the beneficial properties of drugs used to treat either condition. Statins, the mainstay of lipid-lowering therapy, result in a significant clinical benefit both in primary and secondary CVD prevention. In addition to their hypolipidemic capacity, other properties may contribute to statin-induced benefits. Clinical and experimental evidence indicates that statins may modulate blood pressure (BP). The mechanisms by which statins reduce BP seem to be largely independent of their lipid effects. Although small, reductions in BP are possibly clinically relevant. Large landmark studies confirm that statins can reduce CVD risk in hypertensive patients. These findings suggest that statins could be prescribed as an adjunct in treating hypertension with dyslipidemia or even in patients with "normal" cholesterol levels. Whether the effect of statins on BP is accompanied by an additional decrease in clinical outcomes needs to be investigated in long-term, large-scale trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17519121     DOI: 10.1007/s11906-007-0032-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   4.592


  52 in total

1.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

2.  Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones.

Authors:  H Ide; S Fujiya; Y Aanuma; Y Agishi
Journal:  Clin Ther       Date:  1990 Sep-Oct       Impact factor: 3.393

3.  Dyslipidemia and the risk of incident hypertension in men.

Authors:  Ruben O Halperin; Howard D Sesso; Jing Ma; Julie E Buring; Meir J Stampfer; J Michael Gaziano
Journal:  Hypertension       Date:  2005-12-12       Impact factor: 10.190

4.  Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients.

Authors:  Mehmet Kanbay; Aylin Yildirir; Hüseyin Bozbas; Taner Ulus; Muhammet Bilgi; Haldun Muderrisoglu; Ali Akcay; Fatma Nurhan Ozdemir
Journal:  Ren Fail       Date:  2005       Impact factor: 2.606

5.  Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.

Authors:  N Glorioso; C Troffa; F Filigheddu; F Dettori; A Soro; P P Parpaglia; S Collatina; M Pahor
Journal:  Hypertension       Date:  1999-12       Impact factor: 10.190

6.  Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study.

Authors:  Claudio Borghi; Ada Dormi; Maddalena Veronesi; Zina Sangiorgi; Antonio Gaddi
Journal:  Am Heart J       Date:  2004-08       Impact factor: 4.749

7.  Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.

Authors:  O Hernández-Perera; D Pérez-Sala; J Navarro-Antolín; R Sánchez-Pascuala; G Hernández; C Díaz; S Lamas
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

8.  Effects of atorvastatin on vascular remodeling in spontaneously hypertensive rats.

Authors:  Chang-jiang Ge; Shen-jiang Hu; Yao-sen Wu; Nai-yun Chen
Journal:  J Zhejiang Univ Sci       Date:  2003 Sep-Oct

9.  Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.

Authors:  Vasilios G Athyros; Moses Elisaf; Athanasios A Papageorgiou; Athanasios N Symeonidis; Anthimos N Pehlivanidis; Vasilios I Bouloukos; Haralambos J Milionis; Dimitri P Mikhailidis
Journal:  Am J Kidney Dis       Date:  2004-04       Impact factor: 8.860

10.  Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.

Authors:  Giuseppe Derosa; Amedeo Mugellini; Leonardina Ciccarelli; Roberto Fogari
Journal:  Clin Ther       Date:  2003-04       Impact factor: 3.393

View more
  3 in total

Review 1.  Antiplatelet and Lipid-lowering Drugs in Hypertension.

Authors:  Renata Cífková
Journal:  Eur Cardiol       Date:  2014-07

2.  Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study.

Authors:  Anastazia Kei; Moses Elisaf; Elisavet Moutzouri; Stavroula Tsiara; Evangelos Liberopoulos
Journal:  Int J Hypertens       Date:  2011-05-15       Impact factor: 2.420

3.  Implementation of guidelines for the management of arterial hypertension. The impulsion study.

Authors:  Asterios Karagiannis; Apostolos I Hatzitolios; Vasilios G Athyros; Kalliopi Deligianni; Charalambos Charalambous; Christos Papathanakis; Georgios Theodosiou; Theodoros Drakidis; Veronika Chatzikaloudi; Chysanthi Kamilali; Sotirios Matsiras; Athanasios Matziris; Christos Savopoulos; Maria Baltatzi; Jobst Rudolf; Konstantinos Tziomalos; Dimitri P Mikhailidis
Journal:  Open Cardiovasc Med J       Date:  2009-05-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.